A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
130 enrolled
FT576 in Subjects With Multiple Myeloma
Phase 1 Completed
31 enrolled
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Phase 2 Completed
12 enrolled 8 charts
High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma
Phase NA Completed
62 enrolled
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
66 enrolled
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Phase 2 Completed
165 enrolled 15 charts
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Phase 1/2 Completed
87 enrolled 13 charts
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
Phase 1/2 Completed
54 enrolled 13 charts
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Phase 2 Completed
86 enrolled 19 charts
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma
Phase 2 Completed
37 enrolled
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2 Completed
135 enrolled 19 charts
VCAT
Phase 3 Completed
256 enrolled 13 charts
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Phase 3 Completed
660 enrolled
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Phase 3 Completed
389 enrolled
Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide
Phase 2 Completed
62 enrolled
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
Phase 2 Completed
175 enrolled
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
Phase 1 Completed
90 enrolled
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
Phase 2 Completed
150 enrolled
MUKtwelve
Phase 2 Completed
66 enrolled
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Phase 1/2 Completed
45 enrolled
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Allo HSCT Using RIC for Hematological Diseases
Phase 2 Completed
156 enrolled
CCD
Phase 2 Completed
58 enrolled
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
28 enrolled 18 charts
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
Phase 2 Completed
76 enrolled 9 charts
KarMMa-4
Phase 1 Completed
13 enrolled
DCDP
Phase 2 Completed
120 enrolled
CCD
Phase 1/2 Completed
36 enrolled
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Completed
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Phase 2 Completed
25 enrolled 10 charts
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Phase 2 Completed
117 enrolled 27 charts
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Phase 1/2 Completed
28 enrolled
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Phase 2 Completed
422 enrolled 19 charts
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Phase 2 Completed
41 enrolled 12 charts
Autologous Transplant for Multiple Myeloma
Phase 2/3 Completed
363 enrolled 25 charts
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Phase 2 Completed
101 enrolled 17 charts
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Phase 1 Completed
32 enrolled 12 charts
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
Phase 1 Completed
13 enrolled 15 charts
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Phase 1/2 Completed
37 enrolled
aMILs
Phase 2 Completed
36 enrolled 13 charts
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
Phase NA Completed
140 enrolled
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2 Completed
6 enrolled 16 charts
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Phase NA Completed
18 enrolled 7 charts
Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma
Phase 2 Completed
30 enrolled